Prostate Cancer Devices Market is One of The Major Trends Seen in Adoption of Robotic Prostatectomy
The prostate
cancer devices market is growing due to increase in aging population
and increase in research and development in oncology therapeutic area. Limited
players in the market and increasing pharmaceutical expenditure by emerging
markets are some of the factors providing ample opportunities to the prostate
cancer devices market to grow at a considerable rate in the coming years.
Adoption of robotic prostatectomy is one of the major trends seen in the
prostate cancer devices market.
Some of the ways to diagnose prostate cancer are prostate
biopsy, digital rectal exam, pet and spect scans, ultrasound, prostascint
monoclonal antibody scan, prostate-specific antigen blood test, lymph node
biopsy, CT scan, MRI, and bone scan. The causes by which the prostate cancer
occurs are, diet or lifestyle factors, age, infection or inflammation of the
prostate gland, family history or genetics, obesity, and race. Stages of
prostate cancer are categorized as stage I, stage II, stage III and stage IV.
Request to Get the Sample Pages at:
On the basis of products, the prostate cancer devices market
can be categorized as chemotherapy, hormonal therapy and immunotherapy.
Chemotherapy consists of mitoxantrone, taxotere, estramustine and jevtana.
Hormonal therapy consists of luteinizing hormone-releasing hormone antagonists,
anti-androgens and luteinizing hormone-releasing hormone analogs. Luteinizing
hormone-releasing hormone analogs include decapeptyl, lupron, vantas, zoladex
and eligard.
The prostate cancer devices market can be categorized on the
basis of applications as external beam radiation therapy, radical
prostatectomy, cryotherapy, high intensity focused ultrasound (HIFU), robotic
surgery, brachytherapy and laparoscopic surgery. Brachytherapy, also known as
internal radiotherapy, is an emerging early stage treatment option for prostate
cancer. In the treatment, radioactive sources or seeds are placed near the
tumor to give out a high radiation dose to the tumor. Simultaneously, the
radioactive seeds decrease the radiation contact in the surrounding healthy
tissues.
Some of the competitors in the prostate cancer devices
market are Varian Medical Systems, Inc., Galil Medical Inc., Intuitive
Surgical, Inc., Elekta AB, Eckert & Ziegler BEBIG, Siemens Healthcare, and
Philips Healthcare.
Comments
Post a Comment